TD Private Client Wealth LLC Sells 9,696 Shares of GSK plc (NYSE:GSK)

TD Private Client Wealth LLC cut its stake in shares of GSK plc (NYSE:GSK) by 78.1% in the fourth quarter, HoldingsChannel reports. The fund owned 2,726 shares of the pharmaceutical company’s stock after selling 9,696 shares during the period. TD Private Client Wealth LLC’s holdings in GSK were worth $92,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co boosted its position in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust purchased a new position in shares of GSK during the 4th quarter valued at $26,000. ST Germain D J Co. Inc. boosted its holdings in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. increased its stake in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Finally, Sierra Ocean LLC bought a new stake in GSK during the fourth quarter valued at about $32,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Up 0.2 %

Shares of GSK opened at $38.65 on Wednesday. The business’s 50 day simple moving average is $36.90 and its 200-day simple moving average is $36.80. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a market capitalization of $80.00 billion, a price-to-earnings ratio of 24.31, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.07%. GSK’s dividend payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.